Baird lowered the firm’s price target on DexCom (DXCM) to $90 from $112 and keeps an Outperform rating on the shares. The firm updated its model following the mixed Seagrove survey. Baird maintains expanding NIT T2 reimbursement remains key for the company.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: